CNTB is trading at $2.53 (+5.96%) in pre-market after extending its late-June rally. The latest move follows recent momentum in the shares and comes after the company reported completion of enrollment in its Phase 2 Seabreeze STAT Asthma study, with topline data expected in early September 2026.[6]
No new discrete overnight company announcement was found to explain the jump, so the move appears to be continuation strength in a volatile biotech name. Broader markets are slightly higher, but CNTB’s move is larger than the index gains, pointing to stock-specific trading interest.[6]